Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
Originally published on 02/19/2013 in The Journal of Clinical Oncology
The extent of off-label use is a policy concern because the clinical benefits of such use to patients may not outweigh costs or adverse health outcomes.
In this study, Dr. Bach and coauthors find that patent-protected chemotherapies are used approximately 30% of the time for for off-label indications.
Read the full article here.